{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:36:43Z","timestamp":1790289403034,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T00:00:00Z","timestamp":1504828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To compare the sodium\u2010glucose\u2010cotransporter\u20102 (SGLT\u20102) inhibitor dapagliflozin with dipeptidyl peptidase\u20104 (DPP\u20104) inhibitors with regard to risk associations with major adverse cardiovascular (CV) events (MACE; non\u2010fatal myocardial infarction, non\u2010fatal stroke or cardiovascular mortality), hospitalization for heart failure (HHF), atrial fibrillation and severe hypoglycaemia in patients with type 2 diabetes (T2D) in a real\u2010world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients with T2D prescribed glucose\u2010lowering drugs (GLDs) during 2012 to 2015 were identified in nationwide registries in Denmark, Norway and Sweden. Patients were divided into two groups: new users of dapagliflozin and new users of DPP\u20104 inhibitors, matched 1:3 by propensity score, calculated by patient characteristics, comorbidities and drug treatment. Cox survival models were used to estimate hazard ratio (HR) per country separately, and a weighted average was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, a total of 40\u2009908 patients with T2D were identified as new users of dapagliflozin (n\u2009=\u200910\u2009227) or a DPP\u20104 inhibitor (n\u2009=\u200930\u2009681). The groups were well balanced at baseline; their mean age was 61\u2009years and 23% had CV disease. The mean follow\u2010up time was 0.95\u2009years, with a total of 38\u2009760 patient\u2010years. Dapagliflozin was associated with a lower risk of MACE, HHF and all\u2010cause mortality compared with DPP\u20104 inhibitors: HRs 0.79 (95% confidence interval [CI] 0.67\u20100.94), 0.62 (95% CI 0.50\u20100.77), and 0.59 (95% CI 0.49\u20100.72), respectively. Numerically lower, but non\u2010significant HRs were observed for myocardial infarction (0.91 [95% CI 0.72\u20101.16]), stroke (0.79 [95% CI 0.61\u20101.03]) and CV mortality (0.76 [95% CI 0.53\u20101.08]) Neutral associations with atrial fibrillation and severe hypoglycaemia were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dapagliflozin was associated with lower risks of CV events and all\u2010cause mortality compared with DPP\u20104 inhibitors in a real\u2010world clinical setting and a broad T2D population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13077","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T16:18:02Z","timestamp":1501777082000},"page":"344-351","source":"Crossref","is-referenced-by-count":182,"title":["Dapagliflozin is associated with lower risk of cardiovascular events and all\u2010cause mortality in people with type 2 diabetes (\n                    <scp>CVD\u2010REAL Nordic<\/scp>\n                    ) when compared with dipeptidyl peptidase\u20104 inhibitor therapy:\n                    <scp>A<\/scp>\n                    multinational observational study"],"prefix":"10.1111","volume":"20","author":[{"given":"Frederik","family":"Persson","sequence":"first","affiliation":[{"name":"Steno Diabetes Centre  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nystr\u00f6m","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, S\u00f6dersjukhuset  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit E.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Steno Diabetes Centre  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bendix","family":"Carstensen","sequence":"additional","affiliation":[{"name":"Steno Diabetes Centre  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne L.","family":"Gulseth","sequence":"additional","affiliation":[{"name":"Oslo University Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Thuresson","sequence":"additional","affiliation":[{"name":"Statisticon AB  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fenici","sequence":"additional","affiliation":[{"name":"AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nathanson","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, S\u00f6dersjukhuset  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-9481","authenticated-orcid":false,"given":"Jan W.","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Norhammar","sequence":"additional","affiliation":[{"name":"Karolinska Institutet  Stockholm Sweden"},{"name":"Capio S:t G\u00f6rans Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-3967","authenticated-orcid":false,"given":"Johan","family":"Bodegard","sequence":"additional","affiliation":[{"name":"AstraZeneca Nordic\u2010Baltic  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e5re I.","family":"Birkeland","sequence":"additional","affiliation":[{"name":"Oslo University Hospital  Oslo Norway"},{"name":"University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3971-y"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504347"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_7_6_1","unstructured":"The CVD\u2010REAL Investigators and Study Group. CVD\u2010REAL: a multinational retrospective observational study in patients with type 2 diabetes mellitus who are initiating treatment with SGLT\u20102 inhibitor or another glucose\u2010lowering drug. AstraZeneca;2017.https:\/\/www.cvdreal.com\/. Accessed March 10 2017."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029190"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30258-9"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12704"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12412"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12314"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12306"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12889"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.04.055"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.12.004"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4312"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"issue":"42","key":"e_1_2_7_21_1","first-page":"1","article-title":"Multivariate and propensity score matching software with automated balance optimization","volume":"7","author":"Sekhon J","year":"2011","journal-title":"J Stat Softw"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00321-8"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4385"},{"key":"e_1_2_7_24_1","volume-title":"A Language and Environment for Statistical Computing","author":"R Core Team","year":"2015"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0356-y"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.3.699"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2579-0"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.061"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht108"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1142"},{"key":"e_1_2_7_31_1","unstructured":"CavenderMA NorhammarA BirkelandKI et al. Hospitalization for heart failure and death in new users of SGLT2 inhibitors in patients with and without cardiovascular disease: CVD\u2010REAL study. American Diabetes Association \u2013 77th Annual Scientific Sessions; June 13 2017; San Diego CA. Abstract 377\u2010OR."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012832"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2004.12.007"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2008.05.006"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.14.1174"},{"key":"e_1_2_7_38_1","unstructured":"JabbourSA SeufertJ SheenAJ BailyCJ KarupC LangkildeAM. Safety update on dapagliflozin (DAPA) across the phase 2b\/3 clinical trial program. American Diabetes Association 77th Scientific Sessions; June 11 2017; San Diego CA pp 1263\u2010P."},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10180916"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13077","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13077","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13077","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:01:04Z","timestamp":1761872464000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,8]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/dom.13077"],"URL":"https:\/\/doi.org\/10.1111\/dom.13077","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,8]]}}}